354 related articles for article (PubMed ID: 29081214)
1. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
2. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
[TBL] [Abstract][Full Text] [Related]
5. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine.
Mosavat A; Soleimanpour S; Farsiani H; Sadeghian H; Ghazvini K; Sankian M; Jamehdar SA; Rezaee SA
Infect Genet Evol; 2016 Apr; 39():163-172. PubMed ID: 26835592
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis.
Mani R; Gupta M; Malik A; Tandon R; Prasad R; Bhatnagar R; Banerjee N
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30104212
[TBL] [Abstract][Full Text] [Related]
7. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
8. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
[TBL] [Abstract][Full Text] [Related]
9. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
10. Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against
Ullah N; Hao L; Wu Y; Zhang Y; Lei Q; Banga Ndzouboukou JL; Lin X; Fan X
J Immunol Res; 2020; 2020():2083793. PubMed ID: 32953889
[TBL] [Abstract][Full Text] [Related]
11. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
13. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection.
Dietrich J; Billeskov R; Doherty TM; Andersen P
J Immunol; 2007 Mar; 178(6):3721-30. PubMed ID: 17339470
[TBL] [Abstract][Full Text] [Related]
15. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
[TBL] [Abstract][Full Text] [Related]
16. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
17. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.
Grover A; Troudt J; Foster C; Basaraba R; Izzo A
Immunology; 2014 May; 142(1):111-23. PubMed ID: 24350616
[TBL] [Abstract][Full Text] [Related]
18. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
[TBL] [Abstract][Full Text] [Related]
19. Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response.
Wang D; Xu J; Feng Y; Liu Y; Mchenga SS; Shan F; Sasaki J; Lu C
Vaccine; 2010 Apr; 28(18):3134-42. PubMed ID: 20197133
[TBL] [Abstract][Full Text] [Related]
20. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.
Woodworth JS; Clemmensen HS; Battey H; Dijkman K; Lindenstrøm T; Laureano RS; Taplitz R; Morgan J; Aagaard C; Rosenkrands I; Lindestam Arlehamn CS; Andersen P; Mortensen R
Nat Commun; 2021 Nov; 12(1):6658. PubMed ID: 34795205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
